BioTuesdays

Tag - Thomas Shrader

Silence-Therapeutics-Logo

BTIG starts Silence Therapeutics at buy; PT $32

BTIG initiated coverage of Silence Therapeutics (NASDAQ, AIM: SLN) with a “buy” rating and $32 price target. The stock closed at $16.70 on Nov. 17. The company is a development stage therapeutics company based on nearly...

Mersana Therapeutics Logo

BTIG starts Mersana Therapeutics at buy; PT $14

BTIG launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with a “buy” rating and $14 price target. The stock closed at $9.36 on April 28. Mersana is focused on developing antibody-drug conjugates (ADCs) for cancer...

Cue Biopharma Logo

BTIG starts Cue Biopharma at buy; PT $26

BTIG launched coverage of Cue Biopharma (NASDAQ:CUE) with a “buy” rating and $26 price target. The stock closed at $15.51 on Jan. 27. Cue Biopharma exploits signals naturally provided by dendritic cells (DCs) to...

Alector

BTIG starts Alector at buy; PT $28

BTIG initiated coverage of Alector (NASDAQ:ALEC) with a “buy” rating and $28 price target. The stock closed at $15.80 on Nov. 20. Alector is focused on the immune system of the brain as a major player in...

Sutra-Biopharma-Logo

BTIG starts Sutro Biopharma at buy; PT $19

BTIG initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $19 price target. The stock closed at $8.43 on Oct. 4. Sutro exploits rapid DNA-to-protein cycle times of cell free biosynthesis to...

Gritstone Oncology

BTIG starts Gritstone Oncology at buy; PT $26

BTIG launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $26 price target. The stock closed at $15.17 on Oct. 22. Gritstone is a clinical-phase oncology company that specializes in focusing a...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.